UNCY — Unicycive Therapeutics Inc · catalysts, narrative & risks

Overview

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company based in Mountain View, CA, focused on kidney diseases [3], [19]. Its lead candidate, oxylanthanum carbonate (OLC), is an investigational oral phosphate binder being developed for hyperphosphatemia in patients with chronic kidney disease on dialysis [3], [19]. A second candidate, UNI-494, targets acute kidney injury [19]. As of late October 2026 the company's market capitalization was roughly $104M–$134M depending on the date and price snapshot [1], [16], [background], placing it in the small-cap, single-catalyst biotech category. All figures should be treated as point-in-time and verified before use [1].